A novel L band satellite beacon receiver based on Zero IF converter

Li, Rui; Zhao, Long

doi:10.1109/cisp.2011.6100728

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[33] As oral administration of hispidulin reduced fasting blood glucose, we examined whether hispidulin suppresses hepatic gluconeogenesis, which is largely responsible for excessive hepatic glucose output in diabetes. [34] We found that the protein levels of hepatic pyruvate carboxylase (PCB), a key enzyme for gluconeogenesis, were significantly increased in diabetic mice, but were normalized after treatment with hispidulin ( Figure 4). We then isolated and cultured mouse hepatocytes with or without hispidulin treatment, and found that hispidulin directly suppressed glucose production in hepatocytes with the concentration as low as 1 µm already eliciting a significant effect ( Figure 4J), although it is unclear whether this concentration is readily achievable in vivo by dietary intake of this compound.…”

Section: Hispidulin Ameliorates Hyperglycemia In Stz-induced Diabeticmentioning

confidence: 97%

Flavone Hispidulin Stimulates Glucagon‐Like Peptide‐1 Secretion and Ameliorates Hyperglycemia in Streptozotocin‐Induced Diabetic Mice

Wang

Alkhalidy

et al. 2020

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope Loss of functional β‐cell mass is central for the deterioration of glycemic control in diabetes. The incretin hormone glucagon‐like peptide‐1 (GLP‐1) plays a critical role in maintaining glycemic homeostasis via potentiating glucose‐stimulated insulin secretion and promoting β‐cell mass. Agents that can directly promote GLP‐1 secretion, thereby increasing insulin secretion and preserving β‐cell mass, hold great potential for the treatment of T2D. Methods and results GluTag L‐cells, INS832/13 cells, and mouse ileum crypts and islets are cultured for examining the effects of flavone hispidulin on GLP‐1 and insulin secretion. Mouse livers and isolated hepatocytes are used for gluconeogenesis. Streptozotocin‐induced diabetic mice are treated with hispidulin (20 mg kg−1 day−1, oral gavage) for 6 weeks to evaluate its anti‐diabetic potential. Hispidulin stimulates GLP‐1 secretion from the L‐cell line, ileum crypts, and in vivo. This hispidulin action is mediated via activation of cyclic adenosine monophosphate/protein kinase A signaling. Hispidulin significantly improves glycemic control in diabetic mice, concomitant with improved insulin release, and β‐cell survival. Additionally, hispidulin decreases hepatic pyruvate carboxylase expression in diabetic mice and suppresses gluconeogenesis in hepatocytes. Furthermore, hispidulin stimulates insulin secretion from β‐cells. Conclusion These findings suggest that Hispidulin may be a novel dual‐action anti‐diabetic compound via stimulating GLP‐1 secretion and suppressing hepatic glucose production.

show abstract

Section: Hispidulin Ameliorates Hyperglycemia In Stz-induced Diabeticmentioning

confidence: 97%